Exelixis Q3 revenue $411.7M; cabozantinib franchise up 39% YoY; GAAP EPS $0.23

EXELIXIS, INC.

2022-Q3 EPS reported $0.65 revenue$1,187,145,000

Total revenues $411.7M (up 25% YoY); cabozantinib net product revenue $366.5M (+39% YoY).
GAAP net income $73.2M ($0.23 diluted EPS) vs $38.2M ($0.12) prior year; non-GAAP EPS $0.31.
Announced option deals with Cybrexa and Sairopa to access early-stage oncology assets.
Cash and investments $2.1B at quarter end, up from $1.9B at Dec 2021.
R&D expenses $198.8M (up from $163.4M); SG&A $115.0M (up from $101.6M).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

EXELIXIS, INC. reported the quarter ended September 30, 2022 results: revenue $411.7 million, net income $73.2 million, EPS $0.23.

Period: the quarter ended September 30, 2022
Revenue: $411.7 million
Net income: $73.2 million
EPS: $0.23
Result: reported results

Exact text from the filing

EXELIXIS ANNOUNCES THIRD QUARTER 2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Total Revenues of $411.7 million, Cabozantinib Franchise Revenues of $366.5 million - - GAAP Diluted EPS of $0.23, Non-GAAP Diluted EPS of $0.31 -

View on SEC.gov

Browse all earnings releases →

EXELIXIS, INC. filing history →

Source: SEC EDGAR

accession 0000939767-22-000108

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.